$0.99
0.35% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US92511W1080
Symbol
VRCA
Sector
Industry

Verrica Pharmaceuticals Inc Stock price

$0.99
-0.52 34.37% 1M
-7.57 88.42% 6M
-6.33 86.46% YTD
-2.74 73.43% 1Y
-10.12 91.08% 3Y
-15.21 93.88% 5Y
-16.51 94.34% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.35%
ISIN
US92511W1080
Symbol
VRCA
Sector
Industry

Key metrics

Market capitalization $45.19m
Enterprise Value $69.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.53
P/S ratio (TTM) P/S ratio 4.91
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 187.45%
Revenue (TTM) Revenue $9.21m
EBIT (operating result TTM) EBIT $-74.85m
Free Cash Flow (TTM) Free Cash Flow $-59.62m
Cash position $22.96m
EPS (TTM) EPS $-1.83
P/E forward negative
P/S forward 5.83
EV/Sales forward 8.94
Short interest 19.94%
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
20%
Hold
80%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9.21 9.21
188% 188%
100%
- Direct Costs 2.50 2.50
117% 117%
27%
6.71 6.71
226% 226%
73%
- Selling and Administrative Expenses 64 64
101% 101%
699%
- Research and Development Expense 16 16
11% 11%
174%
-74 -74
53% 53%
-799%
- Depreciation and Amortization 1.23 1.23
50% 50%
13%
EBIT (Operating Income) EBIT -75 -75
53% 53%
-813%
Net Profit -85 -85
76% 76%
-923%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
5 days ago
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so...
Neutral
GlobeNewsWire
6 days ago
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either ...
Neutral
PRNewsWire
27 days ago
SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the company's unsuccessful efforts in 2021 and 2022 to secure regulatory approval for its drug product VP-102, designed to treat molluscum. Current shareholders are encouraged to contact the firm.
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 100
Founded 2013
Website www.verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today